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Abstract 
 
Drug self-association can hinder percutaneous penetration. The aim of this study was 
to investigate if disrupting drug-drug interactions using charged nanoparticle surfaces 
could promote delivery of a pharmaceutically active agent into the skin. Tetracaine 
was chosen as a model drug. It was presented to the skin as a hydroxyl 
methylcellulose (HPMC) gel and Ametop gel™ with and without the addition of –ve 
charged silica nanoparticles (NanoSiO2). When the nanoparticles were added to the 
topical formulations it resulted in the fastest drug permeation (109.95 ± 28.63 
µg/cm2/h), highest accumulative mass at 45 min (76.83 ± 18.92 µg) and shortest lag 
time (2.02 ± 0.79 min) in porcine skin. NanoSiO2 disrupted the tetracaine aggregates 
in the HPMC gel whilst not interacting with the polymer to increase the formulation 
macroviscosity. When NanoSiO2were added to the commercial Ametop gel they also 
enhanced penetration through the skin. Despite the very different composition of the 
Ametop system compared to the HPMC the nanoparticles appeared to function in a 
very similar manner, i.e., they broke up the tetracaine aggregates without interacting 
the formulation. The similar results for both the gel systems suggested that, provided 
the drug-nanoparticle interactions were optimised to facilitate drug aggregate break 
up, the addition of solid nanomaterials to semi-solid topical preparations could be a 
novel penetration enhancement method in a number of different types of skin product. 
 
Key words: Tetracaine, nanoparticles, skin, aggregation, gel, skin, permeation. 
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Introduction 
 
Topical drug delivery of a therapeutic agent to the skin presents an attractive alternative 
to other routes of administration by providing a non-invasive strategy that bypasses the 
first pass metabolism, reduces the adverse side-effects of systemic toxicity and improves 
patient compliance [1]. However, efficient topical delivery of therapeutic agents can be 
problematic to achieve due to the relative impermeability of the stratum corneum [2]. If a 
molecule applied topically to the surface of the skin does not have desirable 
physicochemical properties to allow it to move easily into the tissue, the skin barrier can 
reduce or slow the pharmacological response to the administered molecule. A good 
example of a therapeutic agent that is slowed down due to the barrier properties of the 
skin is the topical anaesthetic tetracaine.  
 
Tetracaine is commercially available as Ametop, a 4 % gel that has an onset of action of 
30 – 45 minutes. However, this is too slow for optimal clinical action and this has driven 
formulators to design of a number of strategies to try and improve the clinical use of this 
agent [3-5]. However, it has proven difficult to enhance the permeation of this molecule 
into the skin without the non-reversible modification to the cutaneous tissue. Recent 
studies have shown that one reason for this may be that tetracaine is an amphiphilic drug 
that aggregates in aqueous vehicles [6, 7]. When the drug aggregates it exhibits different 
physiochemical properties in solution compared to the non-aggregated form of the 
molecule [8-11] and at the high tetracaine drug concentrations, i.e., those typically found 
in topical preparations, this physical aggregation can hinder penetration into the skin after 
topical application [12, 13]. Although it has been shown that formulating tetracaine at 
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lower concentrations reduces the aggregation and improves drug transport, using a low 
drug concentration in vivo would reduce its clinical effect [12]. A more clinically viable 
penetration enhancement strategy would be to use a formulation excipient that could 
break up tetracaine aggregation even at high drug concentrations. 
 
Employing nanomaterials in topical products can enhance the percutaneous penetration of 
therapeutic agents [14-16]. Nanomaterials can act as drug carriers, but in addition if solid 
nanomaterials (> 10 nm in size) are added to topical formulations, they can also break up 
drug aggregates without penetrating into the skin through their powerful surface 
interactions. Using nanomaterials to modify drug-drug interactions could be an attractive 
drug delivery approach to improve the action of tetracaine because they may control the 
detrimental effects of this molecules aggregation on the surface of the skin and if the 
added nanomaterials are > 50 nm they are unlikely to enter the body and hence raise 
additional toxicity concerns [17-19].  
 
There have been a number of different mechanisms of action proposed for the penetration 
enhancement properties of nanoparticles include barrier disruption [20, 21], drug 
supersaturation [22, 23], skin occlusion [24, 25] and the provision of a drug reservoir to 
prevent drug depletion [26, 27]. However, there is only one reported study that focuses on 
the ability of nanomaterials to enhance skin penetration through the modification of drug 
aggregation [28]. The drug-nanoparticle surface interactions are probably more important 
when attempting to deliver amphiphilic drugs topically to the skin than the other potential 
penetration enhancing effects aforementioned because the drug nanoparticle surface 
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interactions may alter the drug-drug interaction equilibrium [29-32]. According to Ueda 
et al. (2011) [28], the physical interactions between formulation excipients and drug 
aggregates can be a powerful means to enhanced drug penetration through barriers. In 
addition, it has been shown that drug-nanomaterial interactions can be manipulated 
through varying the properties of the nanomaterials [33]. However, to date a topical 
formulation has not been designed with the purpose of enhancing percutaneous 
penetration simply by the addition of nanomaterials to the preparation in a manner that 
encourages the drug to interact physically with the particle surfaces.  
 
It is also important, if attempting to include nanomaterials in a topical semi-solid product, 
to consider the nanoparticle-vehicle interactions [34]. The vehicle can influence drug 
percutaneous penetration by controlling the drugs thermodynamic activity [35], 
modifying the membrane structure [36, 37] and influencing the diffusion coefficient of 
the drug through the vehicle viscosity [38, 39]. Although a solvent matrix must interact 
with a drug to solubilise it, strong interactions with the solvent should generally be 
avoided because they can have a detrimental effect on skin permeation through changes 
in drug diffusion [40]. This is especially true if trying to increase the penetration of a drug 
from a vehicle using nanoparticles because strong drug-vehicle interactions may 
influence the nanoparticle-drug interactions. 
 
The aim of this study was investigate if percutaneous drug delivery could be enhanced 
from topical gels by disrupting drug-drug interactions using charged nanoparticle 
surfaces. Tetracaine was selected as a model drug as it has previously been shown to 
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aggregate [6, 7], it has a slow onset of action clinically [41] and nanoparticles with a 
negative surface charge have been shown to interact with the drug and modify its 
behaviour [33]. The experiments were conducted in pH 8 because Ametop, the 
commercially marketed gel, was formulated at pH 8 and the aggregation properties of 
tetracaine had been previously studied in this pH [12, 33]. Hydroxypropyl methycellulose 
(HPMC) was chosen as the excipient to produce the novel nanoparticle containing topical 
product due to its inert nature and ability to form a gel with a large pore size which 
usually does not hinder diffusion [42]. A spray formulation was used to apply the HPMC 
system because it was thought to be important to provide the option to apply the 
nanoparticles and gel from different storage reservoirs in order to prevent thickening of 
the gel upon storage with the nanoparticles if strong interactions between the components 
did exist. The sprays were optimised in terms of evaporation kinetics, spray 
characterization, spray recovery and viscosity to ensure accurate dosing. The tetracaine 
permeation from the different formulations was assessed using porcine epidermis as a 
skin model using methods established in previous work [12,13]. Comparisons of the 
HPMC system with the commercially available Ametop were conducted to assess the 
potential for the developed formulation to provide superior drug deposition into the skin 
and to determine if the nanoparticle addition could influence the permeation from 
different types of formulation. Two drug application protocols were used to dose the drug 
to the skin: infinite dose studies were performed to understand the effects of vehicle 
composition on tetracaine delivery; finite dose studies were performed to assess to 
clinical relevance of any differences observed when nanoparticle were added to the 
formulations. Silica nanoparticles (NanoSiO2) were used to represent the nanoparticle 
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surfaces with which the model drug tetracaine could interact. NanoSiO2  were co-
administered to the skin with the drug and no drug was encapsulated into the particles or 
adsorbed onto their surface prior to administration. The semi-solid dosage form’s 
macroviscosity were measured using traditional ‘cone and plate’ rheometry to have a 
better understanding of the interactions taking place in the system, i.e., between the drug, 
nanoparticle and formulation. 
 
Materials and Methods 
 
Materials 
 
HPMC powder (grade 65SH viscosity 400 cP and 50 cP, brand name Metolose) was 
provided by Shin-Etsu Chemical Ltd, Japan. Tetracaine free base (≥ 98%), hydrochloric 
acid, acetic acid and sodium acetate were purchased from Sigma Aldrich, UK. 
Commercially available Ametop gels were supplied by AAH Pharmaceuticals, UK. Silica 
nanoparticles (NanoSiO2 ), with a diameter of 200 nm (Psi-0.2), were obtained from 
Kisker Biotech GmbH and Co., Germany. Ultrapure water (18.2 M) was used 
throughout this study unless stated otherwise. Phosphate-buffered saline tablets were 
supplied by Oxoid Limited, UK. Acetonitrile, methanol and water (high-performance 
liquid chromatography (HPLC grade) were obtained from Fisher Scientific International, 
UK. 
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Spray formulation preparation 
 
The HPMC solutions were prepared by stirring HPMC powder slowly into pH 8 water at 
70 °C and allowing the system to hydrate for 24 h at 5 °C. The formulations were then 
transferred into 50 mL plastic spray bottles (Boots, UK). Three HPMC formulations were 
produced with polymer concentrations of 1 % and 2 % of Grade 65 (viscosity 400 cP, 
65SH400) and 3 % of Grade 65 (viscosity 50 cP, 65SH50) because concentrations above 
these levels were unable to spray through the nozzle of the dosing system used to apply 
them to the skin in the permeation studies. 
 
Evaporation kinetics 
 
Thirty actuations from each spray formulation (i.e. 1 % 65SH400, 2 % 65SH400, 3 % 
65SH50) were applied to a tared weighing boat on an analytical balance and monitored 
for weight loss after application. Weight of the formulation (g) was plotted against time 
(min). The rate of solvent evaporation was calculated using a line of best fit. The study 
lasted for 48 h to ensure the applied formulations were completely dry and no further 
weight loss occurred.  Triplicate experiments were performed. 
 
Spray characterisation 
 
The spray formulation placed at a distance of 5 cm vertically above a piece of filter paper 
and two shots was actuated from the spray canister holding the formulation onto the filter 
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paper. The spray was allowed to dry and the film residue shape was outlined using a 
marker. The shortest diameter and the longest diameter of film residue shape were 
measured. The measurements were used to calculate the area covered by the product 
based on a perfect circle (Eqs, (1) and (2)) and the aspect ratio (AR, Eq. (3))). Triplicate 
measurements were performed for each formulation. 
 
Dmean =  
Dmin+ Dmax
2
 (1) 
Area =  π (
Dmean
2
)
2
   (2) 
AR =  
Dmin
Dmax
     (3) 
 
Spray recovery 
 
Ten actuations from the spray were applied to a tared weighing boat on an analytical 
balance and individually measured. The recovery was calculated as a percentage of the 
sum of the mass of the formulation in the container (Cfinal) and on the tared weighing boat 
(s) at the end of 10 actuations to the initial mass of formulation in the container (Cinitial) 
for each sample, n=3 (Eq. 4). In addition, the amount of formulation recovered in the 
nozzle (nrecover) was measured by the subtraction of the initial mass of nozzle (ninitial) from 
the final mass of the nozzle (nfinal) (Eq. 5).  
 
Recovery (%) =  
Cfinal+s
Cinitial
 ×  100 % (4) 
nrecovery =  nfinal − ninitial  (5)  
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Viscosity of formulation 
 
The rheological measurements were performed using CSL a cone and plate rheometer 
(Carri-med, USA) with plate diameter of 4.0 cm and cone angle of 1.5° at a 100 mm 
fixed gap. The test was performed over a 1-10 Hz frequency range at constant stress 
amplitude of 0.798 Pa. All the measurements were carried out at 20°C. Twenty data 
points were recorded for each rheogram and triplicates were performed for each 
formulation. 
 
Tetracaine transport studies 
 
Fresh white adult porcine ears were obtained from a local abattoir (Evans and Sons, UK). 
Damaged ears were discarded. After cleaning with deionized water and wiping the 
residue with clean wipes, visible hairs were trimmed carefully. The preparation of 
epidermal porcine skin was carried out by heat separation [43]. Porcine skin was 
immersed and gently stirred in deionised water at 60C for 1 min. After removal from the 
deionized water, the skin as put on a corkboard with the dermal side down and the 
epidermis was carefully separated from the dermis with tweezers. The separated 
epidermis was washed with deionized water and floated on filter paper (Whatman no. 1, 
UK) to act as a support before it is dried with clean wipes. The samples were wrapped in 
aluminium foil and stored at - 20C for a maximum of up to 1 month [44]. The samples 
were thawed before use.  
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The transport studies were carried out using upright individually calibrated Franz 
diffusion cells with an average of 2.1 ± 0.1 cm2 surface areas and 9.2 ± 0.5 mL receptor 
compartment volume. The porcine skin was cut, mounted and sealed with parafilm 
between two chambers of the glass diffusion cell with a 13 mm magnetic flea in the 
receiver chamber. The cell was inverted and filled with previously filtered and sonicated 
receiver fluid. Phosphate buffered saline (pH 7.4) was employed as a receiver fluid for 
the porcine epidermis transport studies to mimic the skin environment. The transport 
studies were performed on a submergible magnetic stirrer plate in a pre-heated water bath 
set at 37°C to provide a membrane surface temperature of 32°C. After cell equilibration 
for 1 h, the cells were checked for leaks by inversion and visual inspection for back 
diffusion. The tetracaine test systems were prepared and adjusted to 8.0 using 
hydrochloric acid and equilibrated at 32°C unless stated otherwise. Solutions were stirred 
for at least 24 h and the pH rechecked prior to analysis to ensure they were at 
equilibrium. The vehicle containing the nanoparticles was corrected to the necessary pH 
using hydrochloric acid prior to addition to the tetracaine solutions. The infinite dosing 
studies used 1 mL of tetracaine formulations, which were applied uniformly to the 
surface of the test membrane and the donor compartment was covered with a parafilm to 
minimise donor phase evaporation. In the infinite studies, a saturated tetracaine solution 
of pH 8 was compared to a HPMC formulation (developed in the study) and the 
commercial preparation Ametop. None of the systems contained nanoparticles as the 
objective was to understand the drug-vehicle interactions. The finite dosing tested the 
addition of nanoparticles on the formulations ability to deliver tetracaine in to the skin. 
The nanoparticles were added at a concentration of 50 mg/mL to the tetracaine 
 12 
formulations immediately prior to application to the skin to avoid any potential problems 
induced by chemical or physical instability. The finite dosing transport study used 10 L, 
of Ametop or 3% HPMC formulation. The exact weight of the donor solution applied 
corresponded to 4.87 and 4.85 mg/cm2 respectively. To these two 151 mM drug-loaded 
gels (drug loading was matched across the two formulations) an equal amount (10 L) of 
with silica nanoparticles (NanoSiO2) or water (control) were added to the formulation at 
the 0 h time point after correcting the suspension medium pH to 8. At predetermined time 
intervals, 1 mL aliquots were removed from the Franz cell receiver phases and replaced 
with fresh receiver fluid to keep the liquid volume in the receiver compartment constant. 
The collected receiver fluid samples were analysed by HPLC. A total of 5 replicates of 
each experiment were performed.  
 
Cumulative amounts of drug (ng) penetrating the unit surface of the membrane area (cm2) 
were corrected for sample removal and plotted against time (h). The steady-state flux (J) 
was calculated from the slope of the linear portion of the curve (R2 ≥ 0.98), using at least 
3 points with values above the assay limit of detection (LOQ). The permeability 
coefficient of tetracaine was calculated using equation 6 [45]: 
 
J =  
kp
Cv
                                                            (6)               
 
where J represents the flux, kp is the permeability coefficient of the permeant across the 
membrane and Cv is the concentration of the drug in the vehicle. The flux enhancement 
ratio (ER) of the different formulations was determined using the following equation:  
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ER =  
J2
J1
                                             (7) 
 
where J1 and J2 are the steady-state transmembrane transport rate of tetracaine from the 
tetracaine solutions and tetracaine-nanoparticle gel mixtures respectively. The 
accumulative mass of tetracaine transported through the skin at 45 min was recorded as 
this was the usual onset of action time for this agent. The permeation lag time was 
estimated from the X-axis intercept from the linear regression of the model applied to the 
permeation data in order to determine the flux. 
 
Tetracaine quantification 
 
The quantification of tetracaine was performed using a reverse-phase HPLC system 
consisting of a pump with autosampler (Hewett-Packard series 1050, Agilent 
Technologies UK Ltd., UK) connected to a fluorescence detector (Shimadzu detector RF-
551, Shimadzu corp., Japan). The system was controlled via a computer with Chromeleon 
software (Dionex Corp., USA), which was also used to record and interpret the analytical 
data. The HPLC mobile phase comprised acetonitrile-methanol-acetate buffer (0.1 M) 
(25:25:50 (v/v), pH 5.1) set at a flow rate of 1.0 mL.min-1. Tetracaine was separated 
using a Luna 3 m C18(2) (150 X 4.6 mm) stationary phase (Phenomenex, UK) at room 
temperature with a 100 μL injection volume and the fluorescence detection at an 
excitation wavelength of 310 nm and an emission wavelength of 372 nm. The retention 
time for tetracaine was 4.2 min. The calibration curves were constructed on the basis of 
 14 
the peak area measurements using standard solutions of known tetracaine concentrations 
dissolved in an identical fluid as the receiver phase for the transport studies, 10-4 HCl (pH 
4 water). The assay was shown to be “fit for purpose” in terms of sensitivity (LOD – 4.08 
ng/mL, LOQ – 74 ng/mL, n=25), precision (6% CV), and linearity (R2 ≥ 0.99).  
 
Statistical Analysis 
 
All values were expressed as their mean ± standard deviation (SD). The statistical 
analysis of data was performed using the statistical package for social sciences, SPSS 
version 21, (IBM Corp., USA) with a significance level of 0.05. The normality (Sapiro-
Wilk) and homogeneity of variances (Levene’s test) of the data were assessed prior to 
statistical analysis. Transport data were analysed statistically using one-way analysis of 
variance (ANOVA) tests for normally distributed data and a non-parametric Kruskal-
Wallis tests for non-Gaussian distributed data. Post hoc comparisons of the means of 
individual groups were performed when appropriate using Dunnet’s test for normal 
distributed data and Games Howell test for non-Gaussian distributed data.  For all pair-
wise comparison of means, Student’s independent t-test or Mann-Whitney test was 
applied. Data were presented using OriginPro software (OriginPro version 8.6, OriginLab 
Corporation, US). 
 
 
 
 
 15 
Results 
 
Formulation optimization and characterization 
 
A high spray volume, a high percentage of spray recovery, a low amount of residual in 
the nozzle, a large spray deposit area and a moderately high viscosity were all thought to 
be desirable product characteristics for the spray systems. The rate of evaporation did not 
discriminate between the three formulations (Table 1, p > 0.05, 0.2426 ± 0.0350 g/h), but 
the 2% 65SH400 was thought not to be ideal because it had the lowest spray actuation 
mass (66.7 ± 43.7 mg), lowest percentage spray recovery (99.72 ± 0.09%), highest 
residual nozzle mass after spray actuation (66.0 ± 15.3 mg), lowest mean spray deposit 
diameter (2.4 ± 0.3 cm), lowest mean spray deposit area (4.5 ± 1.1 cm2) and highest 
viscosity (Fig. 1).  
 
The 1% 65SH400 and 3% 65SH50 formulations were not significantly different (p > 
0.05) in terms of the amount of spray actuated (157.7 ± 14.1 mg) and the recovery from 
the spray container (99.83 ± 0.05 %). However, 3% 65SH50 system was chosen for 
further investigation rather than 1% 65SH400 because, although it covered a relatively 
small area (5.9 ± 0.5 cm2), it showed appropriate viscosity to remain on the skin (Fig. 1) 
and it deposited 104-fold less residue on the spray nozzle (p < 0.05). Furthermore, the 3% 
65SH50 gel was the most efficient in terms of ejecting the dose of the three spray 
formulations.  
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Infinite transport studies 
 
Infinite doses of tetracaine were used to understand the effect of vehicle composition on 
tetracaine transport (Table 2, Fig. S2 for permeation profiles). According to 
manufacturer’s data, the commercially available Ametop gel consisted of saturated 
concentrations of tetracaine with sodium hydroxide, sodium methyl-o-hydroxybenzoate, 
sodium propyl-p-hydroxybenzoate, monoboasic potassium phosphate, xanthan gum, 
sodium chloride and purified water. The HPMC formulation consisted of saturated 
concentrations of tetracaine with 3% HPMC. No nanoparticles were added to these 
systems. There was no significant difference (p > 0.05) in steady-state tetracaine transport 
rate ((110.23 ± 40.93 µg/cm2/h) and lag time (9.15 ± 2.05 min) when infinite doses of 
tetracaine were delivered by Ametop and the HPMC formulation compared to a simple 
saturated tetracaine solution, i.e. with no formulation additives. 
 
Finite transport studies 
 
Finite studies were performed to study the transport of tetracaine from the semi-solid 
formulations using a dosing regime that matched clinical conditions (Table 3, Fig S3 and 
S4 for permeation profiles of Ametop and HPMC formulations respectively). Based on 
manufacturer’s data, the  NanoSiO2, which were added to the formulations, only consisted 
of amorphous silica and water. Thus, water acted as a control to mimic the drug dilution 
effects that were experienced upon addition of the nanoparticles to the formulations. 
Calculation of the lag time showed that the HPMC spray, with the added NanoSiO2 , had 
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the shortest permeation lag time (2.02 ± 0.79 min). In addition, the tetracaine permeation 
rate (109.95 ± 28.63 µg/cm2/h) and the amount of tetracaine permeating at the 45 min 
time point (76.83 ± 18.92 µg) were the highest when the drug was formulated as the 
HPMC spray containing the NanoSiO2. The addition of water to the HPMC semi-solid 
formulation did not induce a significant change in tetracaine steady-state flux (30.51 ± 
12.16 µg/cm2/h) and accumulative mass permeating the skin at 45 min (21.99 ± 10.48 
µg), but it did induce a 1.7 times reduction in lag time from 7.09 ± 1.80 min to 3.97 ± 
1.07 min. (Table 3). Compared with the water control, the NanoSiO2  significantly 
enhanced (p<0.05) percutaneous tetracaine transport 3.6 fold when added to the HPMC 
formulation (Table 3). In addition, the NanoSiO2significantly increased the accumulative 
mass at 45 min (m45min) by ca. 3 times and reduced the lag time (tlag) by ca. 2-fold (Table 
3).  
 
In contrast to the HPMC formulation, the addition of water to the Ametop formulations 
significantly enhanced tetracaine permeation rates by 5-fold, increased accumulative 
mass by 10-fold and reduced lag time by 1.5 times (Table 3). Compared to the water 
control, the NanoSiO2 addition to the Ametop formulation increased the skin permeation 
by 2.7. However, of the two formulations tested the HPMC formulation was superior, it 
significantly enhanced the tetracaine flux (46.99 ± 7.96 µg/cm2/h) by 40-fold, increased 
accumulative mass (31.13 ± 4.04 g) by 124-fold and reduced lag time (7.09 ± 1.80 min) 
by 8-fold compared to the Ametop formulation.  
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Rheology measurements 
 
The rheological characteristics of the semi-solid formulations were examined to try and 
further understand the observed differences in the tetracaine permeation profiles (Table 
3). All the Ametop formulations were significantly (p < 0.05) more viscous (higher 
storage and loss modulus) than the HPMC formulations. The addition of water in both 
formulations significantly decreased (p < 0.05) the viscoelasticity of the formulations. 
However, there were no significant changes (p>0.05) in rheological behaviour when the 
additions of water and NanoSiO2 to the gels were compared. 
 
Discussion 
 
Loading tetracaine into a two very different semi solid formulation and applying an 
infinite dose of the systems to the surface of the skin showed no important differences in 
terms of the drug permeation. The data demonstrated that neither the xanthan gum or 
HPMC had a large effect on tetracaine permeation behaviour, i.e. the excipients were 
considered to be relatively inert, when the drug was presented to the skin as in its 
aggregated state (the drug concentration in the formulation was above its measured 
critical aggregation concentration at pH 8 [12]). Similar observations were observed by 
Kim [46] and Charoo [47]. However, HPMC is not inert in all circumstances. In 
supersaturated conditions, HPMC has been shown to interact with a drug and act as an 
anti-nucleating agent [48-50]. To some extent the influence of HPMC on drug 
permeability is dependent on its viscosity and the nature of the drug with which the 
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polymer is formulated with. In the infinite dose studies without nanoparticles tetracaine 
would show strong intermolecular interactions and this may why the interactions with the 
HPMC were limited [12, 13]. The specificity of the drug-vehicle interactions in semi-
solid preparations is one reason why constructing a semi-solid system that facilitates 
efficient release of a drug from a topically applied formulation is not a trivial task. Not 
optimising the drug-vehicle interactions can lead to inefficient delivery. For example, an 
investigation by Shah et al. [51] demonstrated that only 5 – 10 % of the applied 
hydrocortisone was released from commercial creams. To circumvent this problem the 
type of formulation must be matched to the issues presented by the drug. For example, 
Reid et al. [52] showed that EtOH/PEG HFA spray could generate a 6-fold enhancement 
of BMV delivery through the skin as compared to commercial cream, but not one 
approach works for all systems. For example, Fiala et al. [53] used a similar approach to 
Reid et al. [47] when trying to improve the skin penetration of lidocaine, but this was not 
successful. It should be noted that although HPMC did not show the ability to hider the 
delivery of the aggregated tetracaine in the current study viscosity modifiers do generally 
have the potential to hinder drug diffusion from the formulation into the skin. For 
example, the addition of a 7 % gelling agent to thicken a Transcutol:isopropyl myristate 
binary mixture resulted in a four-fold decrease in clebopride diffusion [54].  
 
In the finite dosing studies the –ve charged nanomaterials suspended in water were added 
on the skin just after application of the tetracaine formulations. These systems were 
compared to equivalent semi-solid formulations applied to the skin with an equal amount 
of pH-adjusted water in order to account for the drug dilution effects upon dosing. When 
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the systems with and without nanomaterials were compared across both types of semi-
solid vehicles used in this work, the nanomaterials enhanced drug permeation into the 
skin. It has previously been shown in simple aqueous solvents that NanoSiO2 breaks up 
the tetracaine aggregates due to weak surface interactions between -ve charged NanoSiO2 
surfaces and the + ve charged tetracaine molecules [33]. Although it was likely that the 
same mechanism of action was responsible for the changes in drug permeation shown in 
this study it was thought necessary to further investigate the nature of the drug-vehicle-
nanoparticles interactions in the gels using rheology measurements. 
 
It was interesting that the infinite and finite dosing studies did not show the same results. 
The lack of discrimination between the formulation types in the infinite dosing studies 
was not replicated in the finite dosing studies where the HPMC formulation showed a far 
superior penetration rate into the skin. There is often a significant difference between 
infinite finite dose studies. For example, in a study by Cross et al. [55], thickening agents 
were shown to retard drug penetration through the skin in infinite dose studies but the 
opposite effect was observed in finite dose studies. The authors attributed the different 
results to the increased hydration due to less water evaporation and enhanced drug 
diffusivity through the stratum corneum when using finite doses. It seemed reasonable 
that the same reasons for the differences in the infinite and finite doses from Cross et al.’s 
work [55] could be applied to the current study results.  
 
According to the rheological data, there was no difference between the viscoelasticity of 
the semi-solid formulations when either water or silica particles in water were added to 
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the semi-solid systems. This was unlike the results obtained by Moddaresi et al. [56], 
where an increase in viscoelasticity was observed when lipid nanoparticles were added to 
hyaluronic acid vehicle. This previous work attributed the change in rheological 
behaviour to the presence of strong interactions between the nanoparticles and the 
hyaluronic acid. In the current study the rheology data implied that the formulation 
excipients and the nanoparticles did not display a strong interaction because the addition 
of water and the addition of the nanoparticles suspended in water had the same effect on 
the gel rheology. These results suggested that the superior tetracaine permeation upon the 
addition of nanoparticles was largely due to the other interactions taking place in the 
system, i.e., tetracaine-nanoparticle and/or tetracaine-formulation interactions. The fact 
that the enhanced permeation was observed both in the in-house manufactured HPMC 
formulation and the commercially available Ametop preparation, even though the two 
preparations exhibited very different rheological behaviour, indicated that the tetracaine-
nanoparticle influenced the drug permeation to a greater extent compared to the 
tetracaine-formulation interactions. If the reverse was true then a much larger difference 
in the effects of adding nanoparticles to the gels would be expected. 
 
The addition of water to the tetracaine formulations, regardless of whether or not the 
liquid contained nanoparticles, altered the drug permeation through the skin. This type of 
viscosity dependant permeation behaviour is usually a consequence of the drug forming 
hydrogen bonds with the thickening agent in the topical formulation [59] which reduces 
the drug permeation. The data from the current study showed the opposite effect, i.e. the 
permeation of the drug increased upon the addition of water. As mentioned previously 
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this may have been because of the relatively strong drug-drug affinity of the tetracaine 
molecules (CAC – 7.38 µM [12]) and the weak interactions between the drug on the 
formulation vehicles (as shown by the infinite dosing studies). Alternatively it is also 
possible that the semi-solid system to showed viscosity-independent permeation 
behaviour and the dilution of the system reduced the drug aggregation [57, 58]. 
 
Conclusions 
 
In this study, an efficient tetracaine topical spray formulation with superior drug 
permeability and a more rapid onset of action compared to commercial Ametop was 
generated. This was obtained through the addition of nanoparticles to a semi-solid 
preparation that was sprayed onto the skin. Evidence was gathered to suggest that the 
added nanoparticles primarily interacted with the drug and disrupted the tetracaine 
aggregates, released more free drug to improve drug permeation and lead to a shorter lag 
time. The HPMC spray formulation was thought to be superior to the commercial 
preparation due to the lower macroviscosity, which made tetracaine more readily 
available to permeate through the skin. However, the nanoparticle addition to the 
commercial formulation was also effective in improving the delivery of tetracaine, which 
suggested that this novel drug delivery strategy could even be applied to currently 
marketed products to enhance their performance. 
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Fig. 1 Storage modulus (G’, solid) and loss modulus (G’’, open) measured as a function 
of frequency (Hz) for various 1 % 65SH400 (■), 2 % 65SH400 (●) and 3 % 65SH50 (▲) 
HPMC formulations. Data points represent mean ± standard deviation, n=3. 
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Fig. 2 Storage modulus (G’, top) and loss modulus (G’’, bottom) measured as a function 
of frequency (Hz) for Ametop (■), Ametop with the addition of water (), Ametop with 
the addition of silica nanoparticles, NanoSiO2  ( ), HPMC formulations (▼), HPMC 
formulation with the addition of water (◇), formulation with the addition of NanoSiO2 
( ). Data points represent mean ± standard deviation, n=3. 
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Table 1. Characteristics of various HPMC formulations. Data represent mean ± 
standard deviation of 3 independent tetracaine samples. * Significant differences were 
observed based on one-way ANOVA test. 
 
 
1 % 65SH400 2% 65SH400 3% 65SH50 
Evaporation rate (g/h) 0.24 ± 0.04 0.27 ± 0.03 0.25 ± 0.04 
Spray mass (mg) 157.7 ± 14.1  66.7 ± 43.7* 145.5 ± 27.5 
Spray recovery (%) 99.83 ± 0.05 99.72 ± 0.09* 99.92 ± 0.02 
Nozzle recovery (mg) 31.4 ± 18.2* 66.0 ± 15.3* 0.3 ± 0.1 
Dmean (cm) 3.5 ± 0.1* 2.4 ± 0.3 2.7 ± 0.1 
Area (cm2) 9.8 ± 0.6* 4.5 ± 1.1 5.9 ± 0.5 
Aspect ratio 1.0 ± 0.0 0.9 ± 0.1 0.7 ± 0.1 
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Table 2. Steady state flux and permeability constants, kp, accumulative mass at 45 
minutes, m45min, and lag time, tlag, of infinite dosages of Ametop and tetracaine HPMC 
in the presence of different additives in pH 8 across porcine epidermis membrane. 
Data represent mean ± standard deviation of 3 independent tetracaine samples. 
 
 Flux  
(µg/cm2/h) 
kp  
(10-3 cm/h) 
m45min 
(µg) 
tlag 
(min) 
Saturated solution 110.23 ± 40.93 66.20 ± 24.58 64.5 ±  9.15 ± 2.05 
Ametop formulation 105.36 ± 21.97 63.27 ± 13.19 59.80 ± 9.31 10.10 ± 1.50 
HPMC formulation 107.28 ± 28.31 64.43 ± 17.00 67.19 ± 18.21 8.79 ± 2.43 
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Table 3. Steady state flux, flux enhancement ratio, ER, accumulative mass at 45 min, 
m45min, and lag time, tlag, of finite dosages of Ametop and tetracaine HPMC in the 
presence of different additives in pH 8 across porcine epidermis membrane. Data 
represent mean ± standard deviation of 3 independent tetracaine samples. * Significant 
differences were observed based on one-way ANOVA. 
 
 
 
Flux  
(µg/cm2/h) 
ER m45min 
(µg) 
tlag 
(min) 
Ametop  1.16 ± 0.14 - 0.25 ± 0.06 31.60 ± 3.00 
Ametop + water 5.62 ± 2.25 4.71 ± 1.40* 2.53 ± 1.77* 20.20 ± 1.34* 
Ametop + NanoSiO2 14.19 ± 2.27 12.86 ± 3.16
* 8.12 ± 1.21* 10.69 ± 1.98* 
HPMC 46.99 ± 7.96 - 31.13 ± 4.04 7.09 ± 1.80 
HPMC + water 30.51 ± 12.16 0.69 ± 0.35 21.99 ± 10.48 3.97 ± 1.07* 
HPMC + NanoSiO2  109.95 ± 28.63 2.48 ± 1.08
* 76.83 ± 18.92 * 2.02 ± 0.79* 
 
 
 
 
